Abstract
In order to overcome the pandemic of COVID-19, messenger RNA (mRNA)-based vaccine has been extensively researched as a rapid and versatile strategy. Herein, we described the immunogenicity of mRNA-based vaccines for Beta and the most recent Omicron variants. The homologous mRNA-Beta and mRNA-Omicron and heterologous Ad5-nCoV plus mRNA vaccine exhibited high-level cross-reactive neutralization for Beta, original, Delta, and Omicron variants. It indicated that the COVID-19 mRNA vaccines have great potential in the clinical use against different SARS-CoV-2 variants.
Keywords: Beta; COVID-19; Omicron; mRNA; vaccine.
All Keywords
【저자키워드】 COVID-19, omicron, vaccine., mRNA, Beta, 【초록키워드】 Vaccine, immunogenicity, mRNA vaccine, neutralization, Delta, omicron, variants, SARS-CoV-2 variants, mRNA, Beta, homologous, Heterologous, COVID-19 mRNA vaccine, cross-reactive, Clinical use, Messenger RNA, COVID-19 mRNA vaccines, nCoV, mRNA-based vaccines, pandemic of COVID-19, mRNA-based vaccine, described, indicated, exhibited, overcome, 【제목키워드】 Vaccine, SARS-CoV-2 variant,
【저자키워드】 COVID-19, omicron, vaccine., mRNA, Beta, 【초록키워드】 Vaccine, immunogenicity, mRNA vaccine, neutralization, Delta, omicron, variants, SARS-CoV-2 variants, mRNA, Beta, homologous, Heterologous, COVID-19 mRNA vaccine, cross-reactive, Clinical use, Messenger RNA, COVID-19 mRNA vaccines, nCoV, mRNA-based vaccines, pandemic of COVID-19, mRNA-based vaccine, described, indicated, exhibited, overcome, 【제목키워드】 Vaccine, SARS-CoV-2 variant,
{{{ 추상적인 }}}
COVID-19의 대유행을 극복하기 위해 메신저 RNA(mRNA) 기반 백신이 신속하고 다재다능한 전략으로 광범위하게 연구되었습니다. 여기에서 우리는 Beta와 가장 최근의 Omicron 변이체에 대한 mRNA 기반 백신의 면역원성을 설명했습니다. 동종 mRNA-베타 및 mRNA-오미크론 및 이종 Ad5-nCoV 플러스 mRNA 백신은 베타, 원본, 델타 및 오미크론 변이체에 대해 높은 수준의 교차 반응성 중화를 나타냈습니다. COVID-19 mRNA 백신은 다양한 SARS-CoV-2 변이체에 대한 임상적 사용 가능성이 크다는 것을 나타냈습니다.
{{ 키워드: }} 베타; 코로나바이러스감염증-19 : 코로나19; 오미크론; mRNA; 백신.